Evidence map›Paper›PMID 31367045›Full record

ArticleNature2019

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Anna M Paczulla, Kathrin Rothfelder, Simon Raffel, Martina Konantz, Julia Steinbacher, Hui Wang, Claudia Tandler, Marcelle Mbarga, Thorsten Schaefer, Mattia Falcone and 17 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Review
  4. Leukaemic stem cells go under the radar.Nature reviews. Immunology · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Anna M Paczulla *Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Kathrin Rothfelder *Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany.
Simon Raffel *Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Martina KonantzDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Julia SteinbacherClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany.
Hui WangDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Claudia TandlerClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany.
Marcelle MbargaDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Thorsten SchaeferDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Mattia FalconeHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Eva NievergallHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Daniela DörfelDepartment of Internal Medicine II, Hematology and Oncology, Eberhard-Karls University, Tuebingen, Germany.
Pauline HannsDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Jakob R PasswegDivision of Clinical Hematology, University Hospital Basel, Basel, Switzerland.
Christoph LutzDepartment of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Juerg SchwallerDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Robert ZeiserDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany.
Bruce R BlazarDepartment of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA.
Michael A CaligiuriHematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA, USA.
Stephan DirnhoferInstitute for Pathology & Medical Genetics, University Hospital Basel, Basel, Switzerland.
Pontus LundbergDiagnostic Hematology, Department of Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
Lothar KanzDepartment of Internal Medicine II, Hematology and Oncology, Eberhard-Karls University, Tuebingen, Germany.
Leticia Quintanilla-MartinezInstitute for Pathology, University of Tuebingen, Tuebingen, Germany.
Alexander SteinleInstitute for Molecular Medicine, Goethe University, Frankfurt am Main, Germany.
Andreas TrumppHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.
Helmut R SalihClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tuebingen, Germany.
Claudia LengerkeDepartment of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland. claudia.lengerke@unibas.ch.

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2RR033182 · NCRR · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2011 to 2011
$1.4M
NCRR NIH HHS KL2 RR033182
6 · The paper itself

Abstract

An Amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID31367045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.